Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 241 articles: HTML format

Single Articles

April 2021
1. TAIRA N, Sawaki M, Uemura Y, Saito T, et al
   Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
   J Clin Oncol. 2021 Apr 9:JCO2002751. doi: 10.1200/JCO.20.02751.
   PubMed     Abstract available
   
   
   
2. LOIBL S, Marme F, Martin M, Untch M, et al
   Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
   J Clin Oncol. 2021 Apr 1:JCO2003639. doi: 10.1200/JCO.20.03639.
   PubMed     Abstract available
   
   
   
3. ANDO K, Shimomura A, Yoshimura K, Kawamura Y, et al
   What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
   J Clin Oncol. 2021 Apr 1:JCO2100178. doi: 10.1200/JCO.21.00178.
   PubMed    
   
   
   March 2021
4. FASCHING PA, Yadav S, Hu C, Wunderle M, et al
   Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
   J Clin Oncol. 2021 Mar 29:JCO2001200. doi: 10.1200/JCO.20.01200.
   PubMed     Abstract available
   
   
   
5. CIRUELOS EM, Rugo HS, Mayer IA, Levy C, et al
   Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.
   J Clin Oncol. 2021 Mar 29:JCO2001139. doi: 10.1200/JCO.20.01139.
   PubMed     Abstract available
   
   
   
6. MCDONNELL DP, Wardell SE, Chang CY, Norris JD, et al
   Next-Generation Endocrine Therapies for Breast Cancer.
   J Clin Oncol. 2021 Mar 11:JCO2003565. doi: 10.1200/JCO.20.03565.
   PubMed    
   
   
   February 2021
7. HASHIMOTO K, Shimomura A
   Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer.
   J Clin Oncol. 2021 Feb 25:JCO2003215. doi: 10.1200/JCO.20.03215.
   PubMed    
   
   
   
8. KURIAN AW, Ward KC, Abrahamse P, Bondarenko I, et al
   Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
   J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785.
   PubMed     Abstract available
   
   
   
9. PICCART M, Procter M, Fumagalli D, de Azambuja E, et al
   Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
   J Clin Oncol. 2021 Feb 4:JCO2001204. doi: 10.1200/JCO.20.01204.
   PubMed     Abstract available
   
   
   January 2021
10. BARDIA A, Kaklamani V, Wilks S, Weise A, et al
    Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
    J Clin Oncol. 2021 Jan 29:JCO2002272. doi: 10.1200/JCO.20.02272.
    PubMed     Abstract available
    
    
    
11. KORDE LA, Somerfield MR, Carey LA, Crews JR, et al
    Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
    J Clin Oncol. 2021 Jan 28:JCO2003399. doi: 10.1200/JCO.20.03399.
    PubMed     Abstract available
    
    
    
12. MAGNUSON A, Sedrak MS, Gross CP, Tew WP, et al
    Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer.
    J Clin Oncol. 2021 Jan 14:JCO2002063. doi: 10.1200/JCO.20.02063.
    PubMed     Abstract available
    
    
    December 2020
13. MCNEIL CM
    Coronavirus Farewell.
    J Clin Oncol. 2020;38:4346-4348.
    PubMed    
    
    
    
14. AZIM HA JR, Ameye L, Paesmans M, Lambertini M, et al
    Reply to S. A. Narod et al.
    J Clin Oncol. 2020;38:4352-4354.
    PubMed    
    
    
    
15. MO DC, Luo PH, Huang JF, Huang SX, et al
    Neratinib Plus Capecibine in Patients With HER2-Positive Metastatic Breast Cancer.
    J Clin Oncol. 2020 Dec 17:JCO2002378. doi: 10.1200/JCO.20.02378.
    PubMed    
    
    
    
16. DEKKER TJA
    Neratinib in HER2-Positive Breast Cancer With Brain Metastases.
    J Clin Oncol. 2020 Dec 17:JCO2002385. doi: 10.1200/JCO.20.02385.
    PubMed    
    
    
    
17. DOWSETT M, Sestak I, Cuzick J
    Calibration of CTS5 in Women With Early Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2020 Dec 16:JCO2002551. doi: 10.1200/JCO.20.02551.
    PubMed    
    
    
    
18. SPARANO JA, Crager MR, Tang G, Gray RJ, et al
    Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.
    J Clin Oncol. 2020 Dec 11:JCO2003007. doi: 10.1200/JCO.20.03007.
    PubMed     Abstract available
    
    
    
19. WRIGHT JL, Bellon JR
    Is the Time Right for Five-Fraction Partial Breast Irradiation?
    J Clin Oncol. 2020;38:4135-4137.
    PubMed    
    
    
    
20. BEKELMAN JE, Gupta A, Fishman E, Debono D, et al
    Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
    J Clin Oncol. 2020;38:4055-4063.
    PubMed     Abstract available
    
    
    
21. JAGSI R, Griffith KA, Vicini F, Boike T, et al
    Toward Improving Patients' Experiences of Acute Toxicity From Breast Radiotherapy: Insights From the Analysis of Patient-Reported Outcomes in a Large Multicenter Cohort.
    J Clin Oncol. 2020;38:4019-4029.
    PubMed     Abstract available
    
    
    November 2020
22. WEINSTEIN SP, Korhonen K, Cirelli C, Schnall MD, et al
    Abbreviated Breast Magnetic Resonance Imaging for Supplemental Screening of Women With Dense Breasts and Average Risk.
    J Clin Oncol. 2020;38:3874-3882.
    PubMed     Abstract available
    
    
    
23. RECHT A
    Hypofractionated Whole-Breast Irradiation: Case Closed?
    J Clin Oncol. 2020;38:3584-3586.
    PubMed    
    
    
    
24. WANG SL, Fang H, Hu C, Song YW, et al
    Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China.
    J Clin Oncol. 2020;38:3604-3614.
    PubMed     Abstract available
    
    
    
25. ANG E
    Four Women, One Evening.
    J Clin Oncol. 2020;38:3716-3718.
    PubMed    
    
    
    October 2020
26. NAROD SA, Giannakeas V
    In Response to "Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations".
    J Clin Oncol. 2020 Oct 30:JCO2002253. doi: 10.1200/JCO.20.02253.
    PubMed    
    
    
    
27. TUNG NM, Robson ME, Ventz S, Santa-Maria CA, et al
    TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
    J Clin Oncol. 2020 Oct 29:JCO2002151. doi: 10.1200/JCO.20.02151.
    PubMed     Abstract available
    
    
    
28. BUUS R, Sestak I, Kronenwett R, Ferree S, et al
    Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study.
    J Clin Oncol. 2020 Oct 27:JCO2000853. doi: 10.1200/JCO.20.00853.
    PubMed     Abstract available
    
    
    
29. FERNANDEZ-MARTINEZ A, Krop IE, Hillman DW, Polley MY, et al
    Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
    J Clin Oncol. 2020 Oct 23:JCO2001276. doi: 10.1200/JCO.20.01276.
    PubMed     Abstract available
    
    
    
30. DENDULURI N, Somerfield MR, Chavez-MacGregor M, Comander AH, et al
    Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2020 Oct 20:JCO2002510. doi: 10.1200/JCO.20.02510.
    PubMed     Abstract available
    
    
    
31. BUCHHOLZ TA, Ali S, Hunt KK
    Reply to A. Thomsen et al.
    J Clin Oncol. 2020;38:3577.
    PubMed    
    
    
    
32. ARAOYE EF, Stearns V, Aguh C
    Considerations for the Use of Scalp Cooling Devices in Black Patients.
    J Clin Oncol. 2020;38:3575-3576.
    PubMed    
    
    
    
33. DALLA VOLTA A, Mazziotti G, Maffezzoni F, Grisanti S, et al
    Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.
    J Clin Oncol. 2020;38:3363-3366.
    PubMed    
    
    
    
34. WHELAN T, Levine M, Sussman J
    Hypofractionated Breast Irradiation: What's Next?
    J Clin Oncol. 2020;38:3245-3247.
    PubMed    
    
    
    
35. MODI S, Park H, Murthy RK, Iwata H, et al
    Reply to T.J.A. Dekker.
    J Clin Oncol. 2020;38:3351-3352.
    PubMed    
    
    
    September 2020
36. MULDER RL, Hudson MM, Bhatia S, Landier W, et al
    Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group.
    J Clin Oncol. 2020 Sep 29:JCO2000562. doi: 10.1200/JCO.20.00562.
    PubMed     Abstract available
    
    
    
37. WOLFF AC
    CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?
    J Clin Oncol. 2020 Sep 20:JCO2002688. doi: 10.1200/JCO.20.02688.
    PubMed    
    
    
    
38. JOHNSTON SRD, Harbeck N, Hegg R, Toi M, et al
    Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    J Clin Oncol. 2020 Sep 20:JCO2002514. doi: 10.1200/JCO.20.02514.
    PubMed     Abstract available
    
    
    
39. DE AZAMBUJA E, Ponde N, Gelber RD
    Are We RESPECTing Older Patients With Breast Cancer?
    J Clin Oncol. 2020 Sep 16:JCO2002329. doi: 10.1200/JCO.20.02329.
    PubMed    
    
    
    
40. SAWAKI M, Taira N, Uemura Y, Saito T, et al
    Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
    J Clin Oncol. 2020 Sep 16:JCO2000184. doi: 10.1200/JCO.20.00184.
    PubMed     Abstract available
    
    
    
41. OFFERSEN BV, Alsner J, Nielsen HM, Jakobsen EH, et al
    Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial.
    J Clin Oncol. 2020 Sep 10:JCO2001363. doi: 10.1200/JCO.20.01363.
    PubMed     Abstract available
    
    
    
42. LIGIBEL JA
    Reply to R.T. Chlebowski et al.
    J Clin Oncol. 2020;38:3072-3073.
    PubMed    
    
    
    
43. THOMSEN AR, Vaupel P, Grosu AL, Notter M, et al
    Hyperthermia Plus Re-Irradiation in the Management of Unresectable Locoregional Recurrence of Breast Cancer in Previously Irradiated Sites.
    J Clin Oncol. 2020 Sep 8:JCO2001857. doi: 10.1200/JCO.20.01857.
    PubMed    
    
    
    August 2020
44. MEATTINI I, Marrazzo L, Saieva C, Desideri I, et al
    Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial.
    J Clin Oncol. 2020 Aug 24:JCO2000650. doi: 10.1200/JCO.20.00650.
    PubMed     Abstract available
    
    
    
45. JOHNSTON SRD, Hegg R, Im SA, Park IH, et al
    Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Br
    J Clin Oncol. 2020 Aug 21:JCO2001894. doi: 10.1200/JCO.20.01894.
    PubMed     Abstract available
    
    
    
46. JAFFE ES, Feldman AL, Gaulard P, Miranda RN, et al
    Reply to M. Romero et al.
    J Clin Oncol. 2020;38:2819-2820.
    PubMed    
    
    
    
47. TUNG N, Hacker MR, Garber JE
    Reply to S. Takamizawa et al.
    J Clin Oncol. 2020;38:2700-2701.
    PubMed    
    
    
    
48. TING FIL
    The Road Less Traveled: Serving the Underserved.
    J Clin Oncol. 2020;38:2597-2598.
    PubMed    
    
    
    July 2020
49. NAOUM GE, Roberts S, Brunelle CL, Shui AM, et al
    Quantifying the Impact of Axillary Surgery and Nodal Irradiation on Breast Cancer-Related Lymphedema and Local Tumor Control: Long-Term Results From a Prospective Screening Trial.
    J Clin Oncol. 2020 Jul 30:JCO2000459. doi: 10.1200/JCO.20.00459.
    PubMed     Abstract available
    
    
    
50. RAHBAR H, Lee JM, Lee CI
    Optimal Screening in Breast Cancer Survivors With Dense Breasts on Mammography.
    J Clin Oncol. 2020 Jul 24:JCO2001641. doi: 10.1200/JCO.20.01641.
    PubMed     Abstract available
    
    
    
51. NOORDHOEK I, Blok EJ, Meershoek-Klein Kranenbarg E, Putter H, et al
    Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
    J Clin Oncol. 2020 Jul 24:JCO1902427. doi: 10.1200/JCO.19.02427.
    PubMed     Abstract available
    
    
    
52. SAURA C, Oliveira M, Feng YH, Dai MS, et al
    Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >/= 2 HER2-Directed Regimens: Phase III NALA Trial.
    J Clin Oncol. 2020 Jul 17:JCO2000147. doi: 10.1200/JCO.20.00147.
    PubMed     Abstract available
    
    
    
53. MCDONALD AM, Chen Y, Wu J, Hageman L, et al
    Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report.
    J Clin Oncol. 2020 Jul 16:JCO2000231. doi: 10.1200/JCO.20.00231.
    PubMed     Abstract available
    
    
    
54. LAMBERTINI M, Ameye L, Hamy AS, Zingarello A, et al
    Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations.
    J Clin Oncol. 2020 Jul 16:JCO1902399. doi: 10.1200/JCO.19.02399.
    PubMed     Abstract available
    
    
    
55. BRUNT AM, Haviland JS, Sydenham M, Agrawal RK, et al
    Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.
    J Clin Oncol. 2020 Jul 14:JCO1902750. doi: 10.1200/JCO.19.02750.
    PubMed     Abstract available
    
    
    
56. DEKKER TJA
    HER2-Targeted Therapies in HER2-Low-Expressing Breast Cancer.
    J Clin Oncol. 2020 Jul 13:JCO2000657. doi: 10.1200/JCO.20.00657.
    PubMed    
    
    
    
57. SHUMWAY DA, Momoh AO, Sabel MS, Jagsi R, et al
    Integration of Breast Reconstruction and Postmastectomy Radiotherapy.
    J Clin Oncol. 2020;38:2329-2340.
    PubMed    
    
    
    
58. MORROW M, Khan AJ
    Locoregional Management After Neoadjuvant Chemotherapy.
    J Clin Oncol. 2020;38:2281-2289.
    PubMed    
    
    
    
59. HWANG ES, Solin L
    De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer.
    J Clin Oncol. 2020;38:2230-2239.
    PubMed    
    
    
    
60. WHITE J, Thompson A, Whelan T
    Accelerated Partial Breast Irradiation and Intraoperative Partial Breast Irradiation: Reducing the Burden of Effective Breast Conservation.
    J Clin Oncol. 2020;38:2254-2262.
    PubMed    
    
    
    
61. MAMOUNAS EP, Mitchell MP, Woodward WA
    Molecular Predictive and Prognostic Markers in Locoregional Management.
    J Clin Oncol. 2020;38:2310-2320.
    PubMed    
    
    
    
62. DESMEDT C, Fornili M, Clatot F, Demicheli R, et al
    Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.
    J Clin Oncol. 2020 Jul 2:JCO1901771. doi: 10.1200/JCO.19.01771.
    PubMed     Abstract available
    
    
    
63. CHLEBOWSKI RT, Aragaki AK, Prentice RL
    Dietary Moderation and Deaths From Breast Cancer.
    J Clin Oncol. 2020 Jul 2:JCO2001218. doi: 10.1200/JCO.20.01218.
    PubMed    
    
    
    
64. CATHCART-RAKE EJ, Ruddy KJ
    Smart Technology and Endocrine Therapy Adherence.
    J Clin Oncol. 2020;38:2117-2118.
    PubMed    
    
    
    June 2020
65. PISTILLI B, Paci A, Ferreira AR, Di Meglio A, et al
    Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.
    J Clin Oncol. 2020 Jun 22:JCO1901758. doi: 10.1200/JCO.19.01758.
    PubMed     Abstract available
    
    
    
66. LLUCH A, Barrios CH, Torrecillas L, Martin M, et al
    Reply to Y. Usui et al.
    J Clin Oncol. 2020;38:2113-2114.
    PubMed    
    
    
    
67. AMBROSONE CB, Hutson AD
    Reply to E. Javor et al.
    J Clin Oncol. 2020;38:2111.
    PubMed    
    
    
    
68. ROMERO M, Melo A, Bedoya N, de la Hoz J, et al
    Should Flow Cytometry Be Considered a First Line of Study in the Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma?
    J Clin Oncol. 2020 Jun 17:JCO2000712. doi: 10.1200/JCO.20.00712.
    PubMed    
    
    
    
69. TAKAMIZAWA S, Ishiki H, Shimoi T, Shimizu M, et al
    Neoadjuvant Cisplatin in BRCA Carriers With HER2-Negative Breast Cancer.
    J Clin Oncol. 2020 Jun 9:JCO2000789. doi: 10.1200/JCO.20.00789.
    PubMed    
    
    
    May 2020
70. LIN NU, Borges V, Anders C, Murthy RK, et al
    Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
    J Clin Oncol. 2020 May 29:JCO2000775. doi: 10.1200/JCO.20.00775.
    PubMed     Abstract available
    
    
    
71. TORRES MA, Horst KC, Freedman GM
    Postmastectomy and Regional Nodal Radiation for Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902908. doi: 10.1200/JCO.19.02908.
    PubMed    
    
    
    
72. MITTENDORF EA, Bellon JR, King TA
    Regional Nodal Management in Patients With Clinically Node-Negative Breast Cancer Undergoing Upfront Surgery.
    J Clin Oncol. 2020 May 22:JCO1902891. doi: 10.1200/JCO.19.02891.
    PubMed    
    
    
    
73. HEPEL JT, Wazer DE
    Partial Breast Irradiation Is the Preferred Standard of Care for a Majority of Women With Early-Stage Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902594. doi: 10.1200/JCO.19.02594.
    PubMed    
    
    
    
74. SMITH BD, Goetz MP, Boughey JC
    Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.
    J Clin Oncol. 2020 May 22:JCO1903036. doi: 10.1200/JCO.19.03036.
    PubMed     Abstract available
    
    
    
75. RECHT A
    Whole-Breast Irradiation Is the Preferred Standard of Care for the Majority of Patients With Early-Stage Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902388. doi: 10.1200/JCO.19.02388.
    PubMed    
    
    
    
76. SHAITELMAN SF, Jeruss JS, Pusic AL
    Oncoplastic Surgery in the Management of Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902795. doi: 10.1200/JCO.19.02795.
    PubMed    
    
    
    
77. KUHL CK, Lehman C, Bedrosian I
    Imaging in Locoregional Management of Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1903257. doi: 10.1200/JCO.19.03257.
    PubMed    
    
    
    
78. SCHNITT SJ, Moran MS, Giuliano AE
    Lumpectomy Margins for Invasive Breast Cancer and Ductal Carcinoma in Situ: Current Guideline Recommendations, Their Implications, and Impact.
    J Clin Oncol. 2020 May 22:JCO1903213. doi: 10.1200/JCO.19.03213.
    PubMed    
    
    
    
79. MCLAUGHLIN SA, Brunelle CL, Taghian A
    Breast Cancer-Related Lymphedema: Risk Factors, Screening, Management, and the Impact of Locoregional Treatment.
    J Clin Oncol. 2020 May 22:JCO1902896. doi: 10.1200/JCO.19.02896.
    PubMed    
    
    
    
80. HAFFTY BG, Euhus DM, Pierce LJ
    Genetic Factors in the Locoregional Management of Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902859. doi: 10.1200/JCO.19.02859.
    PubMed    
    
    
    
81. SMITH BD, Mittendorf EA, Haffty BG
    Multidisciplinary Locoregional Management of Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO2000483. doi: 10.1200/JCO.20.00483.
    PubMed    
    
    
    
82. BUCHHOLZ TA, Ali S, Hunt KK
    Multidisciplinary Management of Locoregional Recurrent Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902806. doi: 10.1200/JCO.19.02806.
    PubMed    
    
    
    
83. HERSHMAN DL, Unger JM, Hillyer GC, Moseley A, et al
    Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105.
    J Clin Oncol. 2020 May 5:JCO1902699. doi: 10.1200/JCO.19.02699.
    PubMed     Abstract available
    
    
    April 2020
84. USUI Y, Ishiki H, Shimomura A, Satomi E, et al
    Suggestions Regarding the GEICAM/2003-11_CIBOMA/2004-01 Trial: Future Treatment Options for Early Triple-Negative Breast Cancer.
    J Clin Oncol. 2020 Apr 30:JCO1903406. doi: 10.1200/JCO.19.03406.
    PubMed    
    
    
    
85. TARANTINO P, Hamilton E, Tolaney SM, Cortes J, et al
    HER2-Low Breast Cancer: Pathological and Clinical Landscape.
    J Clin Oncol. 2020 Apr 24:JCO1902488. doi: 10.1200/JCO.19.02488.
    PubMed    
    
    
    
86. JAVOR E, Lucijanic M, Skelin M
    Dietary Supplement Use and Patient Outcomes in High-Risk Early-Stage Breast Cancer.
    J Clin Oncol. 2020 Apr 21:JCO2000091. doi: 10.1200/JCO.20.00091.
    PubMed    
    
    
    
87. LAZZERONI M, DeCensi A
    De-Escalating Treatment of Low-Risk Breast Ductal Carcinoma In Situ.
    J Clin Oncol. 2020;38:1252-1254.
    PubMed    
    
    
    
88. HWANG ES, Hyslop T, Hendrix LH, Duong S, et al
    Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
    J Clin Oncol. 2020;38:1284-1292.
    PubMed     Abstract available
    
    
    
89. PAGANI O, Francis PA, Fleming GF, Walley BA, et al
    Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
    J Clin Oncol. 2020;38:1293-1303.
    PubMed     Abstract available
    
    
    
90. LI J, Yu K, Pang D, Wang C, et al
    Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
    J Clin Oncol. 2020 Apr 10:JCO1902474. doi: 10.1200/JCO.19.02474.
    PubMed     Abstract available
    
    
    
91. WAGNER LI, Gray RJ, Sparano JA, Whelan TJ, et al
    Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.
    J Clin Oncol. 2020 Apr 9:JCO1901866. doi: 10.1200/JCO.19.01866.
    PubMed     Abstract available
    
    
    
92. HORTOBAGYI GN
    Breast Cancer: 45 Years of Research and Progress.
    J Clin Oncol. 2020 Apr 7:JCO2000199. doi: 10.1200/JCO.20.00199.
    PubMed    
    
    
    
93. TUNG NM, Boughey JC, Pierce LJ, Robson ME, et al
    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
    J Clin Oncol. 2020 Apr 3:JCO2000299. doi: 10.1200/JCO.20.00299.
    PubMed     Abstract available
    
    
    
94. STEBBING J, Mainwaring PN, Curigliano G, Pegram M, et al
    Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
    J Clin Oncol. 2020;38:1070-1080.
    PubMed     Abstract available
    
    
    
95. CHIEN AJ, Tripathy D, Albain KS, Symmans WF, et al
    MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
    J Clin Oncol. 2020;38:1059-1069.
    PubMed     Abstract available
    
    
    March 2020
96. BEEBE-DIMMER JL, Kapron AL, Fraser AM, Smith KR, et al
    Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
    J Clin Oncol. 2020 Mar 24:JCO1902808. doi: 10.1200/JCO.19.02808.
    PubMed     Abstract available
    
    
    
97. LIGIBEL JA
    Could the Women's Health Initiative Breathe New Life Into Breast Cancer Prevention?
    J Clin Oncol. 2020 Mar 9:JCO2000148. doi: 10.1200/JCO.20.00148.
    PubMed    
    
    
    
98. GANZ PA, Van Dyk K
    Cognitive Impairment in Patients With Breast Cancer: Understanding the Impact of Chemotherapy and Endocrine Therapy.
    J Clin Oncol. 2020 Mar 6:JCO2000336. doi: 10.1200/JCO.20.00336.
    PubMed    
    
    
    
99. YADAV S, Hu C, Hart SN, Boddicker N, et al
    Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
    J Clin Oncol. 2020 Mar 3:JCO1902190. doi: 10.1200/JCO.19.02190.
    PubMed     Abstract available
    
    
    
100. YANG X, Leslie G, Doroszuk A, Schneider S, et al
     Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
     J Clin Oncol. 2020;38:674-685.
     PubMed     Abstract available
     
     
     February 2020
101. TUNG N, Arun B, Hacker MR, Hofstatter E, et al
     TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
     J Clin Oncol. 2020 Feb 25:JCO1903292. doi: 10.1200/JCO.19.03292.
     PubMed     Abstract available
     
     
     
102. DELALOGE S, Piccart M, Rutgers E, Litiere S, et al
     Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
     J Clin Oncol. 2020 Feb 21:JCO1901371. doi: 10.1200/JCO.19.01371.
     PubMed     Abstract available
     
     
     
103. MODI S, Park H, Murthy RK, Iwata H, et al
     Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
     J Clin Oncol. 2020 Feb 14:JCO1902318. doi: 10.1200/JCO.19.02318.
     PubMed     Abstract available
     
     
     
104. HASSETT MJ, Somerfield MR, Baker ER, Cardoso F, et al
     Management of Male Breast Cancer: ASCO Guideline.
     J Clin Oncol. 2020 Feb 14:JCO1903120. doi: 10.1200/JCO.19.03120.
     PubMed     Abstract available
     
     
     
105. JAFFE ES, Ashar BS, Clemens MW, Feldman AL, et al
     Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.
     J Clin Oncol. 2020 Feb 11:JCO1902778. doi: 10.1200/JCO.19.02778.
     PubMed     Abstract available
     
     
     
106. CHLEBOWSKI RT, Aragaki AK, Anderson GL, Pan K, et al
     Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial.
     J Clin Oncol. 2020 Feb 7:JCO1900435. doi: 10.1200/JCO.19.00435.
     PubMed     Abstract available
     
     
     January 2020
107. RAYSON D
     Camouflage.
     J Clin Oncol. 2020;38:281-282.
     PubMed    
     
     
     
108. ALLISON KH, Hammond MEH, Dowsett M, McKernin SE, et al
     Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
     J Clin Oncol. 2020 Jan 13:JCO1902309. doi: 10.1200/JCO.19.02309.
     PubMed     Abstract available
     
     
     
109. GEIERSBACH KB, Meyer RG, Sill DR, Mounajjed T, et al
     Working Up Group 4 Equivocal HER2 Samples Tested by Fluorescence in Situ Hybridization in a Reference Laboratory Setting: Past, Present, and Future.
     J Clin Oncol. 2020;38:175-176.
     PubMed    
     
     
     
110. HENRY NL, Andre F, Ismaila N, Somerfield MR, et al
     Reply to A. Katz.
     J Clin Oncol. 2020;38:102-103.
     PubMed    
     
     
     
111. KATZ A
     Is It Appropriate to Use the Result of an Unplanned, Exploratory, Nonstatistically Significant Subgroup Analysis to Support a Treatment Recommendation in an ASCO Treatment Guideline?
     J Clin Oncol. 2020;38:102.
     PubMed    
     
     
     December 2019
112. HAYES DF, Rae JM
     Pharmacogenomics and Endocrine Therapy in Breast Cancer.
     J Clin Oncol. 2019 Dec 27:JCO1903119. doi: 10.1200/JCO.19.03119.
     PubMed    
     
     
     
113. AMBROSONE CB, Zirpoli GR, Hutson AD, McCann WE, et al
     Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221).
     J Clin Oncol. 2019 Dec 19:JCO1901203. doi: 10.1200/JCO.19.01203.
     PubMed     Abstract available
     
     
     
114. SCHMID P, Abraham J, Chan S, Wheatley D, et al
     Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
     J Clin Oncol. 2019 Dec 16:JCO1900368. doi: 10.1200/JCO.19.00368.
     PubMed     Abstract available
     
     
     
115. DUMAS A, Vaz Luis I, Bovagnet T, El Mouhebb M, et al
     Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO).
     J Clin Oncol. 2019 Dec 13:JCO1901726. doi: 10.1200/JCO.19.01726.
     PubMed     Abstract available
     
     
     
116. FEHRENBACHER L, Cecchini RS, Geyer CE Jr, Rastogi P, et al
     NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
     J Clin Oncol. 2019 Dec 10:JCO1901455. doi: 10.1200/JCO.19.01455.
     PubMed     Abstract available
     
     
     
117. TAMURA K, Imamura CK, Takano T, Saji S, et al
     CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.
     J Clin Oncol. 2019 Dec 10:JCO1901412. doi: 10.1200/JCO.19.01412.
     PubMed     Abstract available
     
     
     
118. POORVU PD, Gelber SI, Rosenberg SM, Ruddy KJ, et al
     Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
     J Clin Oncol. 2019 Dec 6:JCO1901959. doi: 10.1200/JCO.19.01959.
     PubMed     Abstract available
     
     
     
119. LLUCH A, Barrios CH, Torrecillas L, Ruiz-Borrego M, et al
     Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
     J Clin Oncol. 2019 Dec 5:JCO1900904. doi: 10.1200/JCO.19.00904.
     PubMed     Abstract available
     
     
     
120. VARSHAVSKY-YANOVSKY AN, Goldstein LJ
     Role of Capecitabine in Early Breast Cancer.
     J Clin Oncol. 2019 Dec 5:JCO1902946. doi: 10.1200/JCO.19.02946.
     PubMed    
     
     
     
121. JAYASEKERA J, Mandelblatt JS
     Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions.
     J Clin Oncol. 2019 Dec 5:JCO1901525. doi: 10.1200/JCO.19.01525.
     PubMed    
     
     
     
122. HE W, Grassmann F, Eriksson M, Eliasson E, et al
     CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer.
     J Clin Oncol. 2019 Dec 4:JCO1901535. doi: 10.1200/JCO.19.01535.
     PubMed     Abstract available
     
     
     October 2019
123. SHARMA P, Barlow WE, Godwin AK, Parkes EE, et al
     Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
     J Clin Oncol. 2019 Oct 28:JCO1900693. doi: 10.1200/JCO.19.00693.
     PubMed     Abstract available
     
     
     
124. CHUMSRI S, Li Z, Serie DJ, Mashadi-Hossein A, et al
     Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31.
     J Clin Oncol. 2019 Oct 17:JCO1900443. doi: 10.1200/JCO.19.00443.
     PubMed     Abstract available
     
     
     
125. SJOSTROM M, Chang SL, Fishbane N, Davicioni E, et al
     Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer.
     J Clin Oncol. 2019 Oct 16:JCO1900761. doi: 10.1200/JCO.19.00761.
     PubMed     Abstract available
     
     
     
126. LAMBERTINI M, Blondeaux E, Perrone F, Del Mastro L, et al
     Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.
     J Clin Oncol. 2019 Oct 16:JCO1902242. doi: 10.1200/JCO.19.02242.
     PubMed     Abstract available
     
     
     September 2019
127. HOWIE LJ, Singh H, Bloomquist E, Wedam S, et al
     Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
     J Clin Oncol. 2019 Sep 27:JCO1802217. doi: 10.1200/JCO.18.02217.
     PubMed     Abstract available
     
     
     
128. KIM HA, Lee JW, Nam SJ, Park BW, et al
     Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.
     J Clin Oncol. 2019 Sep 16:JCO1900126. doi: 10.1200/JCO.19.00126.
     PubMed     Abstract available
     
     
     
129. VISVANATHAN K, Fabian CJ, Bantug E, Brewster AM, et al
     Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.
     J Clin Oncol. 2019 Sep 3:JCO1901472. doi: 10.1200/JCO.19.01472.
     PubMed     Abstract available
     
     
     August 2019
130. HINDIE E
     Skipping the Lymphoscintigraphy Step During Sentinel Node Procedures in Breast Cancer: What Information Are We Missing?
     J Clin Oncol. 2019 Aug 29:JCO1901612. doi: 10.1200/JCO.19.01612.
     PubMed    
     
     
     
131. LITTON JK, Scoggins ME, Hess KR, Adrada BE, et al
     Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
     J Clin Oncol. 2019 Aug 28:JCO1901304. doi: 10.1200/JCO.19.01304.
     PubMed     Abstract available
     
     
     
132. JIMENEZ RB, Hickey S, DePauw N, Yeap BY, et al
     Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation.
     J Clin Oncol. 2019 Aug 26:JCO1802366. doi: 10.1200/JCO.18.02366.
     PubMed     Abstract available
     
     
     
133. ABRAHAM J, Montero AJ, Jankowitz RC, Salkeni MA, et al
     Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
     J Clin Oncol. 2019 Aug 23:JCO1900858. doi: 10.1200/JCO.19.00858.
     PubMed     Abstract available
     
     
     
134. MA F, Ouyang Q, Li W, Jiang Z, et al
     Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
     J Clin Oncol. 2019 Aug 20:JCO1900108. doi: 10.1200/JCO.19.00108.
     PubMed     Abstract available
     
     
     
135. CESPEDES FELICIANO EM, Chen WY, Bradshaw PT, Prado CM, et al
     Adipose Tissue Distribution and Cardiovascular Disease Risk Among Breast Cancer Survivors.
     J Clin Oncol. 2019 Aug 1:JCO1900286. doi: 10.1200/JCO.19.00286.
     PubMed     Abstract available
     
     
     July 2019
136. MUSS HB, Polley MC, Berry DA, Liu H, et al
     Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
     J Clin Oncol. 2019 Jul 24:JCO1900647. doi: 10.1200/JCO.19.00647.
     PubMed     Abstract available
     
     
     
137. ROSS M, Geyer CE Jr
     Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?
     J Clin Oncol. 2019 Jul 15:JCO1900877. doi: 10.1200/JCO.19.00877.
     PubMed    
     
     
     
138. MOSKOWITZ CS, Chou JF, Neglia JP, Partridge AH, et al
     Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
     J Clin Oncol. 2019 Jul 1:JCO1802219. doi: 10.1200/JCO.18.02219.
     PubMed     Abstract available
     
     
     
139. OEFFINGER KC, Ford JS, Moskowitz CS, Chou JF, et al
     Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study.
     J Clin Oncol. 2019 Jul 1:JCO1900547. doi: 10.1200/JCO.19.00547.
     PubMed     Abstract available
     
     
     June 2019
140. HINDIE E, Groheux D
     Interim [(18)F]Fluorodeoxyglucose-Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
     J Clin Oncol. 2019 Jun 28:JCO1900776. doi: 10.1200/JCO.19.00776.
     PubMed    
     
     
     
141. RAJAGOPAL PS, Catenacci DVT, Olopade OI
     The Time for Mainstreaming Germline Testing for Patients With Breast Cancer Is Now.
     J Clin Oncol. 2019 Jun 27:JCO1900160. doi: 10.1200/JCO.19.00160.
     PubMed    
     
     
     
142. TAYLOR A, Tischkowitz M
     Caveat Emptor: The Perils of Panel Testing in Hereditary Breast Cancer.
     J Clin Oncol. 2019 Jun 27:JCO1900122. doi: 10.1200/JCO.19.00122.
     PubMed    
     
     
     
143. COPUR MS, Jonglertham P, Zusag T
     Should All Patients With a Diagnosis of Breast Cancer Undergo Expanded Panel Testing?
     J Clin Oncol. 2019 Jun 27:JCO1900064. doi: 10.1200/JCO.19.00064.
     PubMed    
     
     
     
144. GOETZ MP, Suman VJ, Nakamura Y, Kiyotani K, et al
     Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM.
     J Clin Oncol. 2019 Jun 18:JCO1900504. doi: 10.1200/JCO.19.00504.
     PubMed    
     
     
     
145. HENRY NL, Somerfield MR, Abramson VG, Ismaila N, et al
     Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
     J Clin Oncol. 2019 Jun 17:JCO1900948. doi: 10.1200/JCO.19.00948.
     PubMed     Abstract available
     
     
     
146. KANTOR ED, Romano ME
     Phthalate Exposure From Prescription Medications and Breast Cancer Risk.
     J Clin Oncol. 2019 Jun 7:JCO1901003. doi: 10.1200/JCO.19.01003.
     PubMed    
     
     
     
147. CONFORTI F, Pala L
     Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors.
     J Clin Oncol. 2019 Jun 7:JCO1900559. doi: 10.1200/JCO.19.00559.
     PubMed    
     
     
     
148. HURVITZ SA, Martin M, Jung KH, Huang CS, et al
     Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
     J Clin Oncol. 2019 Jun 3:JCO1900882. doi: 10.1200/JCO.19.00882.
     PubMed     Abstract available
     
     
     
149. WOLFF AC, Tung NM, Carey LA
     Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
     J Clin Oncol. 2019 Jun 3:JCO1901159. doi: 10.1200/JCO.19.01159.
     PubMed    
     
     
     May 2019
150. ANDRE F, Ismaila N, Henry NL, Somerfield MR, et al
     Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
     J Clin Oncol. 2019 May 31:JCO1900945. doi: 10.1200/JCO.19.00945.
     PubMed     Abstract available
     
     
     
151. SMITH TG, Troeschel AN, Castro KM, Arora NK, et al
     Perceptions of Patients With Breast and Colon Cancer of the Management of Cancer-Related Pain, Fatigue, and Emotional Distress in Community Oncology.
     J Clin Oncol. 2019 May 17:JCO1801579. doi: 10.1200/JCO.18.01579.
     PubMed     Abstract available
     
     
     
152. FABIAN CJ
     Will a Low-Dose Option Improve Uptake of Tamoxifen for Breast Cancer Risk Reduction?
     J Clin Oncol. 2019 May 13:JCO1900656. doi: 10.1200/JCO.19.00656.
     PubMed    
     
     
     
153. UNTCH M, Jackisch C, Schneeweiss A, Schmatloch S, et al
     NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
     J Clin Oncol. 2019 May 13:JCO1801842. doi: 10.1200/JCO.18.01842.
     PubMed     Abstract available
     
     
     
154. EHRHARDT MJ, Howell CR, Hale K, Baassiri MJ, et al
     Subsequent Breast Cancer in Female Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE).
     J Clin Oncol. 2019 May 10:JCO1801099. doi: 10.1200/JCO.18.01099.
     PubMed     Abstract available
     
     
     
155. KUEMMEL S, Holtschmidt J, Gerber B, Von der Assen A, et al
     Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial.
     J Clin Oncol. 2019 May 1:JCO1802092. doi: 10.1200/JCO.18.02092.
     PubMed     Abstract available
     
     
     April 2019
156. YU KD, Shao ZM
     Comparison of Time-Dependent Contralateral Breast Cancer Incidence Requires Comparable Lengths of Follow-Up.
     J Clin Oncol. 2019 Apr 29:JCO1802468. doi: 10.1200/JCO.18.02468.
     PubMed    
     
     
     
157. AHERN TP, Broe A, Lash TL, Cronin-Fenton DP, et al
     Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study.
     J Clin Oncol. 2019 Apr 17:JCO1802202. doi: 10.1200/JCO.18.02202.
     PubMed     Abstract available
     
     
     
158. KURIAN AW, Ward KC, Howlader N, Deapen D, et al
     Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
     J Clin Oncol. 2019 Apr 9:JCO1801854. doi: 10.1200/JCO.18.01854.
     PubMed     Abstract available
     
     
     
159. FOLDI J, O'Meara T, Marczyk M, Sanft T, et al
     Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools.
     J Clin Oncol. 2019 Apr 3:JCO1801933. doi: 10.1200/JCO.18.01933.
     PubMed    
     
     
     
160. TOLANEY SM, Guo H, Pernas S, Barry WT, et al
     Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
     J Clin Oncol. 2019 Apr 2:JCO1900066. doi: 10.1200/JCO.19.00066.
     PubMed     Abstract available
     
     
     March 2019
161. CHANDARLAPATY S, Razavi P
     Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors.
     J Clin Oncol. 2019 Mar 28:JCO1900090. doi: 10.1200/JCO.19.00090.
     PubMed    
     
     
     
162. FREEDMAN RA, Gelman RS, Anders CK, Melisko ME, et al
     TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
     J Clin Oncol. 2019 Mar 12:JCO1801511. doi: 10.1200/JCO.18.01511.
     PubMed     Abstract available
     
     
     February 2019
163. REGAN MM, Fleming GF, Walley B, Francis PA, et al
     Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.
     J Clin Oncol. 2019 Feb 27:JCO1802433. doi: 10.1200/JCO.18.02433.
     PubMed    
     
     
     
164. TURNER NC, Liu Y, Zhu Z, Loi S, et al
     Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
     J Clin Oncol. 2019 Feb 26:JCO1800925. doi: 10.1200/JCO.18.00925.
     PubMed     Abstract available
     
     
     
165. NITZ U, Gluz O, Clemens M, Malter W, et al
     West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
     J Clin Oncol. 2019 Feb 20:JCO1800028. doi: 10.1200/JCO.18.00028.
     PubMed     Abstract available
     
     
     
166. ATEMA V, van Leeuwen M, Kieffer JM, Oldenburg HSA, et al
     Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial.
     J Clin Oncol. 2019 Feb 14:JCO1800655. doi: 10.1200/JCO.18.00655.
     PubMed     Abstract available
     
     
     
167. PAN K, Bosserman LD, Chlebowski RT
     Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
     J Clin Oncol. 2019 Feb 11:JCO1801360. doi: 10.1200/JCO.18.01360.
     PubMed    
     
     
     
168. DOWSETT M, Turner N
     Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk.
     J Clin Oncol. 2019 Feb 11:JCO1801412. doi: 10.1200/JCO.18.01412.
     PubMed    
     
     
     
169. CONNOLLY RM, Leal JP, Solnes L, Huang CY, et al
     TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
     J Clin Oncol. 2019 Feb 5:JCO2018787986. doi: 10.1200/JCO.2018.78.7986.
     PubMed     Abstract available
     
     
     January 2019
170. HAMY AS, Tury S, Wang X, Gao J, et al
     Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
     J Clin Oncol. 2019 Jan 31:JCO1800636. doi: 10.1200/JCO.18.00636.
     PubMed     Abstract available
     
     
     
171. ARASU VA, Miglioretti DL, Sprague BL, Alsheik NH, et al
     Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk.
     J Clin Oncol. 2019 Jan 9:JCO1800378. doi: 10.1200/JCO.18.00378.
     PubMed     Abstract available
     
     
     December 2018
172. DELLAPASQUA S, Gray KP, Munzone E, Rubino D, et al
     Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.
     J Clin Oncol. 2018 Dec 27:JCO1800296. doi: 10.1200/JCO.18.00296.
     PubMed     Abstract available
     
     
     
173. BEITSCH PD, Whitworth PW, Hughes K, Patel R, et al
     Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
     J Clin Oncol. 2018 Dec 7:JCO1801631. doi: 10.1200/JCO.18.01631.
     PubMed     Abstract available
     
     
     
174. MILLIRON KJ, Griggs JJ
     Advances in Genetic Testing in Patients With Breast Cancer, High-Quality Decision Making, and Responsible Resource Allocation.
     J Clin Oncol. 2018 Dec 7:JCO1801952. doi: 10.1200/JCO.18.01952.
     PubMed    
     
     
     
175. JOHNSTON S, Puhalla S, Wheatley D, Ring A, et al
     Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
     J Clin Oncol. 2018 Dec 6:JCO1801624. doi: 10.1200/JCO.18.01624.
     PubMed     Abstract available
     
     
     November 2018
176. RUHSTALLER T, Giobbie-Hurder A, Colleoni M, Jensen MB, et al
     Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
     J Clin Oncol. 2018 Nov 26:JCO1800440. doi: 10.1200/JCO.18.00440.
     PubMed     Abstract available
     
     
     
177. BURSTEIN HJ, Lacchetti C, Anderson H, Buchholz TA, et al
     Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
     J Clin Oncol. 2018 Nov 19:JCO1801160. doi: 10.1200/JCO.18.01160.
     PubMed     Abstract available
     
     
     October 2018
178. MANDELBLATT JS, Small BJ, Luta G, Hurria A, et al
     Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study.
     J Clin Oncol. 2018 Oct 3:JCO1800140. doi: 10.1200/JCO.18.00140.
     PubMed     Abstract available
     
     
     September 2018
179. CRUZ C, Llop-Guevara A, Garber JE, Arun BK, et al
     Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
     J Clin Oncol. 2018 Sep 21:JCO2018786558. doi: 10.1200/JCO.2018.78.6558.
     PubMed     Abstract available
     
     
     
180. BARDIA A, Parton M, Kummel S, Estevez LG, et al
     Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.
     J Clin Oncol. 2018 Sep 20:JCO2017748392. doi: 10.1200/JCO.2017.74.8392.
     PubMed     Abstract available
     
     
     
181. SEIDMAN AD, Bordeleau L, Fehrenbacher L, Barlow WE, et al
     National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.
     J Clin Oncol. 2018 Sep 13:JCO1800242. doi: 10.1200/JCO.18.00242.
     PubMed     Abstract available
     
     
     
182. BEAU AB, Andersen PK, Vejborg I, Lynge E, et al
     Limitations in the Effect of Screening on Breast Cancer Mortality.
     J Clin Oncol. 2018 Sep 4:JCO2018780270. doi: 10.1200/JCO.2018.78.0270.
     PubMed     Abstract available
     
     
     August 2018
183. GINSBURG O, Brennan P
     Genetic Testing for Breast Cancer in the Era of Multigene Panels: Can We Make an Impact on Population Health?
     J Clin Oncol. 2018 Aug 21:JCO2018793307. doi: 10.1200/JCO.2018.79.3307.
     PubMed    
     
     
     
184. ZHENG Y, Walsh T, Gulsuner S, Casadei S, et al
     Inherited Breast Cancer in Nigerian Women.
     J Clin Oncol. 2018 Aug 21:JCO2018783977. doi: 10.1200/JCO.2018.78.3977.
     PubMed     Abstract available
     
     
     
185. RIMAWI M, Ferrero JM, de la Haba-Rodriguez J, Poole C, et al
     First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase I
     J Clin Oncol. 2018 Aug 14:JCO2017767863. doi: 10.1200/JCO.2017.76.7863.
     PubMed     Abstract available
     
     
     July 2018
186. PARKER PA, Peterson SK, Shen Y, Bedrosian I, et al
     Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer.
     J Clin Oncol. 2018 Jul 25:JCO2018786442. doi: 10.1200/JCO.2018.78.6442.
     PubMed     Abstract available
     
     
     
187. MILLER KD, O'Neill A, Gradishar W, Hobday TJ, et al
     Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).
     J Clin Oncol. 2018 Jul 24:JCO2018792028. doi: 10.1200/JCO.2018.79.2028.
     PubMed     Abstract available
     
     
     
188. HOUSTON TP, Ostroff JS
     Cardiovascular Risk Factors and Breast Cancer.
     J Clin Oncol. 2018 Jul 23:JCO1800041. doi: 10.1200/JCO.18.00041.
     PubMed    
     
     
     
189. HU JJ, Urbanic JJ, Case LD, Takita C, et al
     Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population.
     J Clin Oncol. 2018 Jul 10:JCO2017771790. doi: 10.1200/JCO.2017.77.1790.
     PubMed     Abstract available
     
     
     June 2018
190. RAMAKRISHNA N, Temin S, Chandarlapaty S, Crews JR, et al
     Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.
     J Clin Oncol. 2018 Jun 25:JCO2018792713. doi: 10.1200/JCO.2018.79.2713.
     PubMed     Abstract available
     
     
     
191. GIORDANO SH, Temin S, Chandarlapaty S, Crews JR, et al
     Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.
     J Clin Oncol. 2018 Jun 25:JCO2018792697. doi: 10.1200/JCO.2018.79.2697.
     PubMed     Abstract available
     
     
     
192. LYMAN GH, Greenlee H, Bohlke K, Bao T, et al
     Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.
     J Clin Oncol. 2018 Jun 11:JCO2018792721. doi: 10.1200/JCO.2018.79.2721.
     PubMed     Abstract available
     
     
     
193. SLAMON DJ, Neven P, Chia S, Fasching PA, et al
     Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
     J Clin Oncol. 2018 Jun 3:JCO2018789909. doi: 10.1200/JCO.2018.78.9909.
     PubMed     Abstract available
     
     
     May 2018
194. WOLFF AC, Hammond MEH, Allison KH, Harvey BE, et al
     Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
     J Clin Oncol. 2018 May 30:JCO2018778738. doi: 10.1200/JCO.2018.77.8738.
     PubMed     Abstract available
     
     
     
195. FASCHING PA, Loibl S, Hu C, Hart SN, et al
     BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
     J Clin Oncol. 2018 May 23:JCO2017772285. doi: 10.1200/JCO.2017.77.2285.
     PubMed     Abstract available
     
     
     
196. TAYLOR C, McGale P, Bronnum D, Correa C, et al
     Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data.
     J Clin Oncol. 2018 May 23:JCO2017776351. doi: 10.1200/JCO.2017.77.6351.
     PubMed     Abstract available
     
     
     
197. THAVENDIRANATHAN P, Abdel-Qadir H, Fischer HD, Liu Y, et al
     Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study.
     J Clin Oncol. 2018 May 23:JCO2018779736. doi: 10.1200/JCO.2018.77.9736.
     PubMed     Abstract available
     
     
     
198. DENDULURI N, Chavez-MacGregor M, Telli ML, Eisen A, et al
     Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
     J Clin Oncol. 2018 May 22:JCO2018788604. doi: 10.1200/JCO.2018.78.8604.
     PubMed     Abstract available
     
     
     
199. WANG L, Hong BY, Kennedy SA, Chang Y, et al
     Predictors of Unemployment After Breast Cancer Surgery: A Systematic Review and Meta-Analysis of Observational Studies.
     J Clin Oncol. 2018 May 14:JCO2017773663. doi: 10.1200/JCO.2017.77.3663.
     PubMed     Abstract available
     
     
     
200. LAMBERTINI M, Moore HCF, Leonard RCF, Loibl S, et al
     Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
     J Clin Oncol. 2018 May 2:JCO2018780858. doi: 10.1200/JCO.2018.78.0858.
     PubMed     Abstract available
     
     
     April 2018
201. SHERMAN KA, Przezdziecki A, Alcorso J, Kilby CJ, et al
     Reducing Body Image-Related Distress in Women With Breast Cancer Using a Structured Online Writing Exercise: Results From the My Changed Body Randomized Controlled Trial.
     J Clin Oncol. 2018 Apr 24:JCO2017763318. doi: 10.1200/JCO.2017.76.3318.
     PubMed     Abstract available
     
     
     
202. HAMOOD R, Hamood H, Merhasin I, Keinan-Boker L, et al
     Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study.
     J Clin Oncol. 2018 Apr 24:JCO2017763524. doi: 10.1200/JCO.2017.76.3524.
     PubMed     Abstract available
     
     
     
203. DEGNIM AC, Winham SJ, Frank RD, Pankratz VS, et al
     Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia.
     J Clin Oncol. 2018 Apr 20:JCO2017759480. doi: 10.1200/JCO.2017.75.9480.
     PubMed     Abstract available
     
     
     
204. DOWSETT M, Sestak I, Regan MM, Dodson A, et al
     Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
     J Clin Oncol. 2018 Apr 20:JCO2017764258. doi: 10.1200/JCO.2017.76.4258.
     PubMed     Abstract available
     
     
     
205. WHEELER SB, Spencer JC, Pinheiro LC, Carey LA, et al
     Financial Impact of Breast Cancer in Black Versus White Women.
     J Clin Oncol. 2018 Apr 18:JCO2017776310. doi: 10.1200/JCO.2017.77.6310.
     PubMed     Abstract available
     
     
     
206. KORNBLUM N, Zhao F, Manola J, Klein P, et al
     Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of
     J Clin Oncol. 2018 Apr 17:JCO2017769331. doi: 10.1200/JCO.2017.76.9331.
     PubMed     Abstract available
     
     
     
207. WANG SY, Dang W, Richman I, Mougalian SS, et al
     Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
     J Clin Oncol. 2018 Apr 16:JCO2017765941. doi: 10.1200/JCO.2017.76.5941.
     PubMed     Abstract available
     
     
     
208. REINER AS, Sisti J, John EM, Lynch CF, et al
     Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
     J Clin Oncol. 2018 Apr 5:JCO2017773424. doi: 10.1200/JCO.2017.77.3424.
     PubMed     Abstract available
     
     
     March 2018
209. HERSHMAN DL, Till C, Shen S, Wright JD, et al
     Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.
     J Clin Oncol. 2018 Mar 27:JCO2017774414. doi: 10.1200/JCO.2017.77.4414.
     PubMed     Abstract available
     
     
     
210. MASSARWEH SA, Sledge GW, Miller DP, McCullough D, et al
     Molecular Characterization and Mortality From Breast Cancer in Men.
     J Clin Oncol. 2018 Mar 27:JCO2017768861. doi: 10.1200/JCO.2017.76.8861.
     PubMed     Abstract available
     
     
     
211. JAGSI R, Griffith KA, Bellon JR, Woodward WA, et al
     Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.
     J Clin Oncol. 2018 Mar 20:JCO2017772665. doi: 10.1200/JCO.2017.77.2665.
     PubMed     Abstract available
     
     
     
212. UNTCH M, von Minckwitz G, Gerber B, Schem C, et al
     Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
     J Clin Oncol. 2018 Mar 15:JCO2017759175. doi: 10.1200/JCO.2017.75.9175.
     PubMed     Abstract available
     
     
     
213. KATZ SJ, Ward KC, Hamilton AS, Mcleod MC, et al
     Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.
     J Clin Oncol. 2018 Mar 12:JCO2017762369. doi: 10.1200/JCO.2017.76.2369.
     PubMed     Abstract available
     
     
     
214. WEDAM SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, et al
     US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.
     J Clin Oncol. 2018 Mar 9:JCO2017746917. doi: 10.1200/JCO.2017.74.6917.
     PubMed     Abstract available
     
     
     February 2018
215. WHARAM JF, Zhang F, Lu CY, Wagner AK, et al
     Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment.
     J Clin Oncol. 2018 Feb 28:JCO2017752501. doi: 10.1200/JCO.2017.75.2501.
     PubMed     Abstract available
     
     
     
216. ZARDAVAS D, Te Marvelde L, Milne RL, Fumagalli D, et al
     Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
     J Clin Oncol. 2018 Feb 22:JCO2017748301. doi: 10.1200/JCO.2017.74.8301.
     PubMed     Abstract available
     
     
     
217. WAPNIR IL, Price KN, Anderson SJ, Robidoux A, et al
     Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.
     J Clin Oncol. 2018 Feb 14:JCO2017765719. doi: 10.1200/JCO.2017.76.5719.
     PubMed     Abstract available
     
     
     
218. KENNEDY L, Bhatta S, Hechmati G, Buchanan J, et al
     Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases.
     J Clin Oncol. 2018 Feb 1:JCO2017770115. doi: 10.1200/JCO.2017.77.0115.
     PubMed    
     
     
     January 2018
219. NEUMAN HB, Schumacher JR, Francescatti AB, Adesoye T, et al
     Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01).
     J Clin Oncol. 2018 Jan 31:JCO2017755389. doi: 10.1200/JCO.2017.75.5389.
     PubMed     Abstract available
     
     
     
220. PIVOT X, Bondarenko I, Nowecki Z, Dvorkin M, et al
     Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive E
     J Clin Oncol. 2018 Jan 26:JCO2017740126. doi: 10.1200/JCO.2017.74.0126.
     PubMed     Abstract available
     
     
     
221. TRAINA TA, Miller K, Yardley DA, Eakle J, et al
     Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
     J Clin Oncol. 2018 Jan 26:JCO2016713495. doi: 10.1200/JCO.2016.71.3495.
     PubMed     Abstract available
     
     
     
222. LAENKHOLM AV, Jensen MB, Eriksen JO, Rasmussen BB, et al
     PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
     J Clin Oncol. 2018 Jan 25:JCO2017746586. doi: 10.1200/JCO.2017.74.6586.
     PubMed     Abstract available
     
     
     
223. HAWLEY ST, Li Y, An LC, Resnicow K, et al
     Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial.
     J Clin Oncol. 2018 Jan 24:JCO2017748442. doi: 10.1200/JCO.2017.74.8442.
     PubMed     Abstract available
     
     
     
224. DIELI-CONWRIGHT CM, Courneya KS, Demark-Wahnefried W, Sami N, et al
     Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial.
     J Clin Oncol. 2018 Jan 22:JCO2017757526. doi: 10.1200/JCO.2017.75.7526.
     PubMed     Abstract available
     
     
     
225. HOLOWATYJ AN, Cote ML, Ruterbusch JJ, Ghanem K, et al
     Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
     J Clin Oncol. 2018 Jan 17:JCO2017745448. doi: 10.1200/JCO.2017.74.5448.
     PubMed     Abstract available
     
     
     
226. ZIVANOVIC BUJAK A, Dawson SJ
     Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer.
     J Clin Oncol. 2018 Jan 3:JCO2017765461. doi: 10.1200/JCO.2017.76.5461.
     PubMed    
     
     
     
227. STOVER DG, Parsons HA, Ha G, Freeman SS, et al
     Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
     J Clin Oncol. 2018 Jan 3:JCO2017760033. doi: 10.1200/JCO.2017.76.0033.
     PubMed     Abstract available
     
     
     December 2017
228. BUTOW PN, Turner J, Gilchrist J, Sharpe L, et al
     Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.
     J Clin Oncol. 2017;35:4066-4077.
     PubMed     Abstract available
     
     
     
229. JOHNSTON SRD, Hegg R, Im SA, Park IH, et al
     Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Br
     J Clin Oncol. 2017 Dec 15:JCO2017747824. doi: 10.1200/JCO.2017.74.7824.
     PubMed     Abstract available
     
     
     
230. BLUM JL, Robert N, Andersen J, Favret A, et al
     Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer.
     J Clin Oncol. 2017 Dec 11:JCO2017753756. doi: 10.1200/JCO.2017.75.3756.
     PubMed    
     
     
     November 2017
231. HENRY NL, Unger JM, Schott AF, Fehrenbacher L, et al
     Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
     J Clin Oncol. 2017 Nov 14:JCO2017746651. doi: 10.1200/JCO.2017.74.6651.
     PubMed     Abstract available
     
     
     
232. HWONG AR, Mangurian C
     Improving Breast Cancer Screening and Care for Women With Severe Mental Illness.
     J Clin Oncol. 2017 Nov 2:JCO2017760462. doi: 10.1200/JCO.2017.76.0462.
     PubMed    
     
     
     October 2017
233. GANZ PA, Romond EH, Cecchini RS, Rastogi P, et al
     Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Pacl
     J Clin Oncol. 2017 Oct 26:JCO2017741165. doi: 10.1200/JCO.2017.74.1165.
     PubMed     Abstract available
     
     
     
234. JEMAL A, Robbins AS, Lin CC, Flanders WD, et al
     Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013.
     J Clin Oncol. 2017 Oct 16:JCO2017737932. doi: 10.1200/JCO.2017.73.7932.
     PubMed     Abstract available
     
     
     
235. VAN POZNAK C, Somerfield MR, Barlow WE, Biermann JS, et al
     Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
     J Clin Oncol. 2017 Oct 16:JCO2017754614. doi: 10.1200/JCO.2017.75.4614.
     PubMed     Abstract available
     
     
     
236. SHAPIRO CL, Moriarty JP, Dusetzina S, Himelstein AL, et al
     Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
     J Clin Oncol. 2017 Oct 12:JCO2017737437. doi: 10.1200/JCO.2017.73.7437.
     PubMed     Abstract available
     
     
     
237. ASDOURIAN MS, Swaroop MN, Sayegh HE, Brunelle CL, et al
     Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral Surgery.
     J Clin Oncol. 2017 Oct 4:JCO2017737494. doi: 10.1200/JCO.2017.73.7494.
     PubMed     Abstract available
     
     
     
238. GOETZ MP, Toi M, Campone M, Sohn J, et al
     MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
     J Clin Oncol. 2017 Oct 2:JCO2017756155. doi: 10.1200/JCO.2017.75.6155.
     PubMed     Abstract available
     
     
     September 2017
239. WU JW, Azoulay L, Majdan A, Boivin JF, et al
     Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
     J Clin Oncol. 2017 Sep 27:JCO2017734491. doi: 10.1200/JCO.2017.73.4491.
     PubMed     Abstract available
     
     
     
240. IGLAY K, Santorelli ML, Hirshfield KM, Williams JM, et al
     Impact of Preexisting Mental Illness on All-Cause and Breast Cancer-Specific Mortality in Elderly Patients With Breast Cancer.
     J Clin Oncol. 2017 Sep 21:JCO2017734947. doi: 10.1200/JCO.2017.73.4947.
     PubMed     Abstract available
     
     
     February 2017
241. LYMAN GH, Somerfield MR, Bosserman LD, Perkins CL, et al
     Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
     J Clin Oncol. 2017;35:561-564.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: